Key facts
- This page summarizes Elizabeth E. Tallett's Form 4 filing for Moderna, Inc. (MRNA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 May 2025, 16:36.
Elizabeth E. Tallett - 30 Apr 2025 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- Director
- Issuer ticker
- MRNA
- Reported as of
- 30 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 May 2025, 16:36:15 UTC
- Prior SEC filing
- 17 May 2024
- Next SEC filing
- 04 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Sandstrom, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Elizabeth E. Tallett filed Form 4 for Moderna, Inc. (MRNA) on 01 May 2025.
Change
- Previous filing in this sequence was filed on 17 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +19,134
- Change %
- Price
- $0.000000
- Shares after
- 19,134
- Date
- 30 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,134
- Exercise price
- $28.54
- Footnotes
- F1
MRNA
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +4,058
- Change %
- Price
- $0.000000
- Shares after
- 4,058
- Date
- 30 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,058
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option will become fully vested and exercisable on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.
Footnote F2
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F3
The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.